Company Dynamics - Zhou Zhiwen, a major shareholder and actual controller of Zhaoyan New Drug (603127.SH), has announced a significant share reduction plan, potentially cashing out over 500 million yuan based on the current stock price [2] - Before the reduction, Zhou held 74,725,981 shares, accounting for 9.9704% of the total share capital, with a combined holding of 32.274% with his spouse, Feng Yuxia [2] - Following the announcement of the share reduction, Zhaoyan New Drug's stock dropped by 6.20% on December 30, closing at 34.80 yuan, indicating a potential cash-out of over 500 million yuan from the sale of 14.98 million shares [2] Industry Insights - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, gaining prominence in the capital market due to its assets in experimental monkeys [2] - The average market price of experimental monkeys has seen significant fluctuations, with prices rising from 13,800 yuan per monkey in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] - In November 2023, the price of experimental monkeys dropped to approximately 113,000 yuan each, reflecting a decrease of over 30% from the peak [3] - Despite a decline in revenue by 26.23% year-on-year to 985 million yuan in the first three quarters of 2025, Zhaoyan New Drug managed to achieve a net profit of 80.71 million yuan, indicating a recovery in performance [3] - As of December 29, 2025, Zhaoyan New Drug's stock price has increased by over 120% within the year [3] Shareholder Activity - Zhou Zhiwen has a history of share reductions, having sold a total of 14.11 million shares since November 2020, resulting in approximately 915 million yuan in cash [4]

Core Viewpoint - The stock price of Zhaoyan New Drug (603127.SH) surged due to the rebound in the market price of experimental monkeys, prompting major shareholder Zhou Zhiwen to announce a significant share reduction plan, potentially cashing out over 500 million yuan [1] Group 1: Shareholder Actions - Zhou Zhiwen plans to reduce his holdings by up to 14,980,000 shares, representing 20.0466% of his holdings and 1.99873% of the company's total share capital, within three months after the announcement [1] - Prior to the reduction, Zhou Zhiwen held 74,725,981 shares, accounting for 9.9704% of the company, with the couple's total holding at 32.274% [1] - Following the announcement of the share reduction, Zhaoyan New Drug's stock fell by 6.20% to a closing price of 34.80 yuan [1] Group 2: Company Overview - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, with a notable focus on experimental monkeys, which are critical for various research fields [2] - The price of experimental monkeys has fluctuated significantly, with the average market price rising from 13,800 yuan in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] Group 3: Financial Performance - In Q1 2024, Zhaoyan New Drug reported a revenue of 325 million yuan, a year-on-year decrease of 12.07%, and a net loss of 272 million yuan, attributed to a 284 million yuan loss from changes in the fair value of biological assets [3] - By the first three quarters of 2025, the company achieved a revenue of 985 million yuan, a year-on-year decrease of 26.23%, but turned a profit with a net income of 80.71 million yuan [3] - The stock price of Zhaoyan New Drug increased by over 120% throughout the year, reflecting a recovery in the market price of experimental monkeys [3] Group 4: Market Perception - Some market analysts argue that Zhaoyan New Drug primarily sells experimental services rather than monkeys, suggesting that monkey prices do not directly reflect the company's sustainable profitability [4] - Despite this, fluctuations in the value of experimental monkeys significantly impact the company's financial performance, leading to potential distortions in financial reporting [4]

Group 1 - The company held its second extraordinary general meeting of shareholders on December 5, 2025, with no resolutions being rejected [2][3] - The total number of shares with voting rights at the meeting was 746,174,300 shares after excluding shares held in the company's repurchase account [2] - The meeting was convened in accordance with the Company Law and the company's articles of association, with the chairman presiding over the meeting [3] Group 2 - The company approved several governance-related proposals, including the cancellation of the supervisory board and amendments to the articles of association [4][5] - All proposals related to the revision of governance systems and rules were passed unanimously [5][6] - The meeting was attended by all directors and supervisors, and the voting procedures were deemed valid [4][7] Group 3 - The company announced an expected related party transaction with Shengtong Intelligent Technology Co., Ltd., for a total amount not exceeding 16.5 million yuan for the year 2026 [11][12] - The transaction involves the provision of digital services and does not constitute a major asset reorganization [11] - The company had previously engaged in related transactions with Shengtong Intelligent amounting to 993.18 million yuan, which did not exceed 5% of the latest audited net assets [11][12] Group 4 - The company’s main business is non-clinical drug research services, and the collaboration with Shengtong Intelligent is expected to enhance operational efficiency and reduce costs [18] - The pricing for the services provided by Shengtong Intelligent will be based on a cost-plus model, ensuring alignment with market rates [16] - The independent directors and the board approved the related party transaction, confirming it aligns with the company's operational needs [19][20] Group 5 - The company plans to engage in daily related party transactions with Shuyitai Shen (Beijing) Biopharmaceutical Co., Ltd., which have been approved by the board [58][60] - These transactions are necessary for daily operations and are priced at market rates, ensuring no harm to the interests of the company or minority shareholders [65][66] - The company maintains its independence, with no reliance on these transactions for its main business or revenue [66] Group 6 - The company announced plans for entrusted financial management for 2026, with a maximum daily balance of 2 billion yuan for investments in low-risk financial products [69][72] - The purpose of the financial management is to enhance the efficiency of idle funds while ensuring the company's normal operations are not affected [71][78] - The board approved the financial management plan, which includes strict risk control measures [76][78] Group 7 - The company elected a new employee representative director, Li Ye, during the first meeting of the labor union committee on December 5, 2025 [79][80] - The new board will consist of 10 members, including 5 non-independent directors and 4 independent directors, complying with relevant regulations [79][80] - Li Ye has been with the company since 2007 and holds shares in the company, ensuring no conflicts of interest [80]

Core Viewpoint - Zhaoyan New Drug's stock price has experienced fluctuations, with a year-to-date increase of 67.23%, but recent declines in the short term [1][2] Company Overview - Zhaoyan New Drug Research Center Co., Ltd. was established on February 25, 1998, and listed on August 25, 2017. The company primarily focuses on non-clinical safety evaluation services for drugs and preclinical research services, with a revenue composition of 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from experimental model supply [1][2] Financial Performance - For the period from January to September 2025, Zhaoyan New Drug reported operating revenue of 985 million yuan, a year-on-year decrease of 26.23%. However, the net profit attributable to the parent company was 80.71 million yuan, reflecting a significant year-on-year increase of 214.79% [2] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders for Zhaoyan New Drug reached 96,500, an increase of 57.61% compared to the previous period. The average circulating shares per person remained at 0 [2] - Notable changes in institutional holdings include a decrease in shares held by Huabao Zhongzheng Medical ETF and new entries from Guangfa Small Cap Growth Mixed Fund and Guangfa Innovation Upgrade Mixed Fund [3]

Core Viewpoint - The stock of Zhaoyan New Drug has shown significant volatility, with a year-to-date increase of 70.06%, but recent declines in the short term raise concerns about its performance [1][2]. Group 1: Stock Performance - As of November 25, Zhaoyan New Drug's stock price increased by 2.02% to 28.23 CNY per share, with a trading volume of 162 million CNY and a turnover rate of 0.92%, resulting in a total market capitalization of 21.158 billion CNY [1]. - The stock has experienced a decline of 9.89% over the last five trading days, 15.48% over the last 20 days, and 14.14% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent occurrence on September 15 [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhaoyan New Drug reported a revenue of 985 million CNY, a year-on-year decrease of 26.23%, while the net profit attributable to shareholders increased by 214.79% to 80.706 million CNY [2]. - The company has distributed a total of 703 million CNY in dividends since its A-share listing, with 356 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Zhaoyan New Drug reached 96,500, an increase of 57.61% compared to the previous period [2]. - The top ten circulating shareholders include notable funds, with Huabao Zhongzheng Medical ETF holding 12.484 million shares, a decrease of 2.1693 million shares from the previous period, while new shareholders include Guangfa Small Cap Growth Mixed Fund [3].

Group 1 - The core viewpoint of the news highlights the stock performance and financial metrics of Zhaoyan New Drug, indicating a 99.22% increase in stock price year-to-date, with a recent slight decline in the last five and twenty trading days [1][2] - As of September 30, 2025, Zhaoyan New Drug reported a revenue of 985 million yuan, a year-on-year decrease of 26.23%, while the net profit attributable to shareholders increased by 214.79% to 80.71 million yuan [2] - The company has a market capitalization of 24.785 billion yuan and has seen significant trading activity, with a net inflow of 1.4684 million yuan from major funds [1] Group 2 - Zhaoyan New Drug's main business involves non-clinical safety evaluation services for drugs, accounting for 95.59% of its revenue, with clinical services and experimental model supply making up the remainder [1] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed in the last three years [3] - The number of shareholders increased by 57.61% to 96,500 as of September 30, 2025, indicating growing interest in the stock [2]

Core Viewpoint - Zhaoyan New Drug is a leading player in the domestic non-clinical safety evaluation industry, focusing on drug preclinical research services and sales of experimental animals and related products [1] Group 1: Business Performance - In Q3 2025, Zhaoyan New Drug reported revenue of 985 million yuan, ranking 9th in the industry, with the top competitor WuXi AppTec at 32.857 billion yuan [2] - The main business revenue from non-clinical research services was 639 million yuan, accounting for 95.59% of total revenue [2] - The net profit for the same period was 80.706 million yuan, ranking 15th in the industry [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 14.81%, lower than the industry average of 22.79% [3] - The gross profit margin for the same period was 21.55%, below the industry average of 37.70% [3] Group 3: Executive Compensation - The chairman, Feng Yuxia, received a salary of 2.5738 million yuan in 2024, a decrease of 635,600 yuan from 2023 [4] - The general manager, Gao Dapeng, earned 1.7384 million yuan in 2024, down 162,900 yuan from the previous year [4] Group 4: Shareholder Information - As of December 31, 2020, the number of A-share shareholders decreased by 6.87% to 16,700 [5] - The average number of circulating A-shares held per shareholder increased by 7.84% [5] Group 5: Market Outlook - Guolian Securities noted that the company's H1 2025 performance met expectations, with a stable growth in new orders [6] - The total order amount at the end of the reporting period was approximately 2.3 billion yuan, with new orders of about 1.02 billion yuan, reflecting a year-on-year growth of 13.3% [6] - Huaxi Securities adjusted revenue forecasts for 2025-2027 to 1.651 billion, 1.678 billion, and 1.762 billion yuan, respectively [7]

Core Viewpoint - The company is experiencing a phase of performance pressure due to industry cyclicality, but there are signs of order growth and potential improvement in financial results in the future [3]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 669 million yuan, a year-on-year decline of 21.29%. The net profit attributable to the parent company was 61 million yuan, marking a return to profitability, while the net profit excluding non-recurring items was 23 million yuan, also indicating a return to profitability [1]. - In Q2 2025, the company reported operating revenue of 381 million yuan, a year-on-year decline of 27.32%. The net profit attributable to the parent company was 20 million yuan, down 80.67%, and the net profit excluding non-recurring items was -2.61 million yuan [1]. - The company's non-clinical drug research services generated revenue of 639 million yuan in H1 2025, down 21.07% year-on-year, while clinical services generated 29 million yuan, down 26.82% [2]. Profitability Analysis - The laboratory services segment faced significant profit pressure, contributing a net loss of approximately 970 million yuan in H1 2025, a decline of 537.54% year-on-year, primarily due to increased competition leading to a drop in gross margin (24.03%, down 6.34 percentage points) [2]. - The company’s financial management income contributed approximately 320 million yuan to net profit, while the fair value changes of biological assets contributed about 880 million yuan, likely due to a slight increase in the price of experimental monkeys [2]. Order Trends - The total order amount on hand for the company in H1 2025 was approximately 2.3 billion yuan, showing a recovery from about 2.2 billion yuan in Q1 2025. New orders signed in H1 2025 amounted to approximately 1.02 billion yuan, a significant increase from about 900 million yuan in H1 2024 [2]. International Strategy - The company is focusing on expanding its overseas market, achieving operating revenue of 252 million yuan from international operations in H1 2025, a year-on-year increase of 7.13%, with overseas revenue accounting for 37.69% of total revenue [4]. - Over the past two and a half years, the company has signed nearly 500 foreign application projects, with over 90% being dual submissions in China and the U.S. The company has obtained various international industry qualifications to support its international business [4]. Profit Forecast - The company forecasts operating revenues of 1.812 billion yuan, 2.087 billion yuan, and 2.406 billion yuan for 2025, 2026, and 2027, respectively. The net profits attributable to the parent company are expected to be 230 million yuan, 296 million yuan, and 367 million yuan for the same years, with corresponding diluted EPS of 0.31 yuan, 0.40 yuan, and 0.49 yuan [5].

Investment Rating - The report assigns a "Hold" rating for the stock, indicating that the stock price is expected to fluctuate within ±5% of the benchmark [13]. Core Views - The report highlights that the company's performance is under pressure due to industry cyclicality, but there is a marginal acceleration in order growth, suggesting potential improvement in future financial results [2][3]. - The company is focusing on expanding its overseas market presence, with international revenue showing a year-on-year increase of 7.13% in the first half of 2025, accounting for 37.69% of total revenue [4][5]. Summary by Sections Financial Performance - In the first half of 2025, the company reported total revenue of 669 million yuan, a year-on-year decline of 21.29%. The net profit attributable to the parent company was 61 million yuan, marking a return to profitability [1][2]. - The laboratory services segment experienced a significant decline in profit, with a net loss of approximately 97 million yuan, primarily due to increased competition leading to a drop in gross margin [2]. - The company had an order backlog of approximately 2.3 billion yuan as of the first half of 2025, indicating a recovery from the previous quarter [2]. Market Expansion - The company has signed nearly 500 projects for international submissions over the past two and a half years, with over 90% of these projects being dual submissions in China and the United States [4]. - The internationalization strategy is supported by comprehensive industry qualifications, enabling smooth operations in global markets [4]. Earnings Forecast - The company is projected to achieve revenues of 1.812 billion yuan, 2.087 billion yuan, and 2.406 billion yuan for the years 2025, 2026, and 2027, respectively. The net profit attributable to the parent company is expected to be 230 million yuan, 296 million yuan, and 367 million yuan for the same years [7].

Investment Rating - The investment rating for the company is "Buy" for both A and H shares, maintained from previous assessments [7]. Core Views - The company's 1H25 revenue and net profit attributable to shareholders were CNY 66.9 million and CNY 6.1 million respectively, showing a year-on-year decline of 21.3% in revenue but a significant increase of 135.9% in net profit, aligning with performance forecasts [1]. - The overall order backlog stands at approximately CNY 2.3 billion, with new orders amounting to CNY 1.02 billion, reflecting a year-on-year increase of 13.3%, and a notable recovery in new orders in 2Q25 with an 18.0% year-on-year growth [1][4]. - The company is expected to benefit from a continued recovery in industry demand and a well-structured overseas business expansion, indicating strong long-term growth potential [1][4]. Financial Performance - The gross margin for 1H25 was 24.0%, down 6.3 percentage points year-on-year, primarily due to pressure on domestic order volume and the completion of high-margin long-term projects by the end of 2024 [2]. - Operating cash flow for 1H25 was CNY 163 million, representing a year-on-year increase of 3.2%, indicating stable cash flow performance [2]. Business Segments - Non-clinical drug research services generated revenue of CNY 639 million, down 21.1% year-on-year, attributed to short-term pressures in domestic business, while overseas revenue in this segment grew by 7.1% [3]. - Clinical services and others reported revenue of CNY 29.02 million, down 26.8% year-on-year, with several service varieties progressing through NMPA inspections [3]. - The experimental model supply segment generated revenue of CNY 480,000, with ongoing development in non-human primate models and small animal models [3]. Geographic Revenue Breakdown - Overseas revenue reached CNY 252 million, up 7.1% year-on-year, accounting for 37.7% of total revenue, with expectations for continued growth in this area [4]. - Domestic revenue was CNY 417 million, down 32.2% year-on-year, primarily due to historical pressures on order volume and pricing, but there are expectations for marginal improvement in domestic business [4]. Profit Forecast and Valuation - The profit forecast remains unchanged, with expected net profits attributable to shareholders of CNY 292 million, CNY 360 million, and CNY 445 million for 2025-2027 [5]. - The company is positioned as a leader in the domestic non-clinical safety evaluation industry, with a solid technical foundation and active overseas expansion, leading to a target price of CNY 37.02 and HKD 27.34 for A and H shares respectively [5].